# BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation.

 To view the full press release, visit https://ibn.fm/OjVf3

 About TransCode Therapeutics

 TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

 For more information, please visit https://ir.transcodetherapeutics.com/

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-transcode-therapeutics-inc-nasdaq-rnaz-advances-phase-1a-trial-of-rna-cancer-therapy-ttx-mc138/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/transcode-therapeutics-reports-positive-results-in-phase-1a-trial-of-ttx-mc138-for-metastatic-cancer/a1f691465dc0f3d8e41404f7ea7cca66) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1kcbfnb/transcode_therapeutics_reports_positive_results/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/1/pondPcb4.webp)